Budd-Chiari Syndrome

  1. Overview and Definition
  2. Pathophysiology
  3. Causes and Risk Factors
  4. Clinical Presentation
  5. Diagnosis and Imaging
  6. Treatment Approach
  7. Prognosis and Outcomes
  8. Key Research Papers
  9. Connections
  10. Featured Videos

Overview and Definition

Budd-Chiari Syndrome (BCS) is a rare but serious disorder defined by obstruction of hepatic venous outflow — affecting the hepatic veins, the suprahepatic inferior vena cava (IVC), or both — at any level from the small hepatic venules to the right atrium. The obstruction can be thrombotic, membranous, or caused by extrinsic compression, and it leads uniformly to hepatic venous congestion, sinusoidal hypertension, and ultimately ischemic hepatocellular injury.

First described by the British physician George Budd in 1845 and elaborated by the Austrian pathologist Hans Chiari in 1899, BCS is now understood to be a heterogeneous syndrome rather than a single disease. Its annual incidence is approximately 1 per million in Western populations, though higher rates are reported in Asia and Africa — regions where membranous obstruction of the IVC (MOVC) is more prevalent.

BCS affects adults predominantly, with a peak incidence in the third and fourth decades of life, and women are slightly more affected than men, partly reflecting the contribution of oral contraceptive use and pregnancy to thrombotic risk. Without treatment, acute or subacute BCS carries a poor prognosis, but modern stepwise management — anticoagulation, interventional radiology, and liver transplantation — has dramatically improved survival to more than 70% at 5 years in experienced centers.

Back to Table of Contents

Pathophysiology

The central event in BCS is obstruction of hepatic venous drainage. Because the liver receives approximately 25% of cardiac output and has no alternative venous outflow, occlusion of the hepatic veins produces an immediate and severe rise in sinusoidal pressure.

Sinusoidal Hypertension and Congestion

Elevated sinusoidal pressure causes plasma to leak into the space of Disse and then into the peritoneal cavity, producing the characteristic ascites of BCS. Unlike portal hypertension from cirrhosis — where portal pressure rises due to fibrosis and nodular regeneration — the primary abnormality in BCS is venous outflow obstruction. The result is a high-protein, high-gradient ascitic fluid that can accumulate rapidly and is often disproportionately large relative to the degree of liver dysfunction.

Ischemic Hepatocellular Damage

As venous congestion worsens, hepatic arterial inflow becomes relatively inadequate to maintain hepatocyte oxygenation. Centrilobular (zone 3) hepatocytes — furthest from the portal tracts and most dependent on sinusoidal blood flow — undergo ischemic necrosis first. In acute BCS this manifests as centrilobular necrosis and sinusoidal dilatation on biopsy. In chronic BCS, the necrosis evolves into centrilobular fibrosis, nodular regenerative hyperplasia, and eventually cirrhosis.

Portal Hypertension

Hepatic venous congestion and parenchymal fibrosis both raise portal pressure, leading to the full syndrome of portal hypertension: varices (esophageal, gastric, ectopic), splenomegaly, thrombocytopenia, and hepatic encephalopathy in advanced disease. The portal hypertension of BCS is distinct from the "presinusoidal" type seen in portal vein thrombosis — it originates at the sinusoidal level and is compounded by outflow obstruction.

Caudate Lobe Hypertrophy: The Pathognomonic Sign

The caudate lobe is unique among hepatic segments: its small accessory hepatic veins drain directly into the IVC rather than through the three main hepatic veins. When the hepatic veins are obstructed, the caudate lobe alone retains normal venous drainage and therefore escapes the congestion that damages the rest of the liver. The preserved blood supply, combined with compensatory regenerative drive, causes the caudate lobe to undergo dramatic hypertrophy. On imaging, a disproportionately enlarged caudate lobe is virtually pathognomonic of BCS and helps distinguish it from other causes of hepatomegaly and portal hypertension.

Back to Table of Contents

Causes and Risk Factors

BCS is classified into primary (intrinsic venous occlusion, almost always thrombotic) and secondary (extrinsic compression or invasion) forms. Identifying the underlying cause is critical both for treatment and for prognosis, since most primary BCS is driven by an identifiable, treatable thrombophilia.

Primary BCS: Thrombotic Occlusion

Approximately 75% of patients with primary BCS have an identifiable prothrombotic disorder. In many patients, multiple concurrent risk factors are present — a finding that argues for comprehensive thrombophilia testing in every case.

Myeloproliferative Neoplasms (MPN) and JAK2 V617F

Myeloproliferative neoplasms are the single most common cause of BCS in Western populations, accounting for 35–50% of cases. Among them, polycythemia vera is most frequent, followed by essential thrombocythemia and primary myelofibrosis. The JAK2 V617F point mutation — a somatic gain-of-function mutation in the Janus kinase 2 gene that drives MPN — is present in 40–50% of patients with "idiopathic" BCS, even when peripheral blood counts appear normal and the full clinical picture of MPN is not yet apparent. Testing for JAK2 V617F is therefore mandatory in every BCS patient. The mutation produces a mildly hypercoagulable, hyperviscous state that preferentially thromboses the hepatic and portal veins.

Antiphospholipid Syndrome (APS)

APS — defined by persistent antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein-I) plus arterial or venous thrombosis — accounts for approximately 10–25% of BCS cases. In patients with underlying SLE, the risk is compounded by the lupus-associated hypercoagulable state.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH is a clonal hematopoietic disorder caused by a somatic PIG-A mutation that renders blood cells susceptible to complement-mediated destruction. The hemolysis releases free hemoglobin and promotes nitric oxide scavenging, activating platelets and endothelium. PNH is a particularly important cause of BCS because it is treatable with eculizumab (complement C5 inhibitor), and its diagnosis is often overlooked. Flow cytometry for GPI-anchored proteins (CD55/CD59) should be performed in all BCS patients.

Inherited and Acquired Thrombophilias

Oral Contraceptive Pills (OCP) and Pregnancy

Exogenous estrogens — particularly combined oral contraceptives — are an independent risk factor for venous thromboembolism, and hepatic vein thrombosis in women of reproductive age is often the presenting event that reveals an underlying thrombophilia that had previously gone undetected. Pregnancy induces a physiological hypercoagulable state; BCS presenting in the third trimester or postpartum period can be difficult to distinguish from HELLP syndrome or acute fatty liver of pregnancy.

Secondary BCS: Extrinsic Obstruction

Secondary BCS results from structures outside the veins compressing or invading the hepatic venous outflow. Causes include:

Sinusoidal Obstruction Syndrome (SOS) / Veno-Occlusive Disease (VOD)

SOS/VOD is a distinct form of hepatic venous outflow obstruction affecting the terminal hepatic venules and hepatic sinusoids rather than the major hepatic veins. It is most commonly seen after high-dose conditioning chemotherapy for hematopoietic stem cell transplantation (especially busulfan + cyclophosphamide regimens) and after ingestion of pyrrolizidine alkaloids (herbal teas containing comfrey or senecio). SOS does not appear on Doppler ultrasound of the hepatic veins but causes identical sinusoidal congestion and is treated with defibrotide in severe cases.

Back to Table of Contents

Clinical Presentation

The clinical presentation of BCS spans a wide spectrum determined by the speed of onset, the completeness of venous occlusion, and the adequacy of collateral venous drainage. Three main clinical forms are recognized.

Acute BCS

Acute BCS develops over days to a few weeks and presents dramatically with the triad of:

  1. Right upper quadrant (RUQ) pain: often severe and constant, reflecting rapid hepatic capsular distension from edema and congestion.
  2. Tender hepatomegaly: the liver is enlarged, smooth, and exquisitely tender — in contrast to the hard, irregular liver of cirrhosis.
  3. Rapidly accumulating ascites: high-protein, serum-ascites albumin gradient (SAAG) >1.1 g/dL ascites develops within days.

Jaundice, nausea, and vomiting are common. A minority of acute BCS cases progress to acute liver failure (ALF) with encephalopathy, coagulopathy, and multiorgan failure — a fulminant presentation that carries very high short-term mortality without emergency liver transplantation.

Subacute and Chronic BCS (Most Common)

Most patients with BCS — approximately 60–70% — present in the subacute or chronic form, characterized by a more insidious course over weeks to months. The cardinal features are:

Over time, untreated chronic BCS leads to cirrhosis, portal hypertensive bleeding from esophageal varices, and hepatic encephalopathy.

Fulminant BCS

Fulminant BCS is rare (<5% of cases) and represents acute liver failure occurring within 8 weeks of symptom onset in a patient with no pre-existing liver disease. It carries the worst short-term prognosis and should be listed for emergency liver transplantation immediately, as recovery with medical therapy alone is exceptional.

Incidental (Asymptomatic) BCS

An increasing proportion of BCS is diagnosed incidentally during imaging performed for unrelated reasons, particularly as Doppler ultrasound and cross-sectional abdominal imaging have become routine. Asymptomatic BCS may reflect partial occlusion with adequate collateral drainage, and management must be individualized.

Back to Table of Contents

Diagnosis and Imaging

The diagnosis of BCS requires demonstrating obstruction of hepatic venous outflow by imaging. A systematic workup then identifies the underlying cause and guides treatment selection.

Doppler Ultrasound: First-Line Imaging

Doppler ultrasound of the hepatic veins and IVC is the initial investigation of choice. It is rapid, non-invasive, and highly sensitive in experienced hands. Key findings include:

MRI with Contrast

Gadolinium-enhanced MRI provides the most detailed characterization of BCS. It precisely defines the anatomy of hepatic vein and IVC obstruction, identifies parenchymal perfusion defects (heterogeneous enhancement with peripheral patchy hypoperfusion), quantifies caudate lobe enlargement, and detects nodular regenerative hyperplasia or early HCC. MRI is preferred over CT when planning interventional procedures because of its superior soft-tissue contrast without ionizing radiation.

CT with Contrast

Contrast-enhanced CT is often the first cross-sectional study performed and reliably demonstrates hepatic vein occlusion, caudate hypertrophy, and the characteristic "flip-flop" enhancement pattern — peripheral low attenuation (congestion) in the early phase with central enhancement on delayed imaging. CT is also superior to MRI for evaluating the IVC anatomy and planning endovascular intervention.

Thrombophilia Workup

Every patient with confirmed BCS must undergo a comprehensive thrombophilia screen. Testing should be performed before anticoagulation if possible (or after a 4–6 week washout), and results must be interpreted in the context of liver disease, which depletes natural anticoagulants (protein C, S, antithrombin) independently of inherited deficiency. The minimum workup includes:

  1. JAK2 V617F mutation (PCR or allele-specific PCR) — the single most important test
  2. PNH screen (flow cytometry for CD55/CD59 on RBCs and granulocytes)
  3. Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta-2-GP1 IgG/IgM) — two measurements 12 weeks apart for diagnosis
  4. Factor V Leiden (PCR)
  5. Prothrombin G20210A mutation (PCR)
  6. Protein C activity and antigen
  7. Protein S total and free antigen (confounded by liver disease and OCP use)
  8. Antithrombin activity
  9. MTHFR mutation + fasting homocysteine
  10. CBC + peripheral smear (polycythemia, thrombocytosis suggesting MPN)
  11. Serum EPO level (suppressed in polycythemia vera)
  12. Bone marrow biopsy if MPN suspected clinically or by JAK2 positivity

Liver Biopsy

Liver biopsy is not required for the diagnosis of BCS but provides crucial prognostic information: the degree of centrilobular necrosis, fibrosis, and nodular regeneration helps determine urgency of intervention and guides transplant listing decisions. Transjugular liver biopsy (performed at the same session as hepatic venography) is preferred over percutaneous biopsy to avoid bleeding complications in patients with coagulopathy and ascites.

Back to Table of Contents

Treatment Approach

Treatment of BCS follows a stepwise algorithm that aims to relieve venous outflow obstruction, prevent thrombus extension, treat the underlying cause, and manage complications of portal hypertension. The EASL Clinical Practice Guidelines (2016) and AASLD recommendations provide the current framework.

Step 1: Anticoagulation (All Patients)

Anticoagulation is the cornerstone of BCS management and should be started immediately in all patients with confirmed thrombotic BCS, including those with thrombocytopenia or mild coagulopathy. There is no evidence that thrombocytopenia (even platelet counts >50 × 10⁹/L) increases bleeding risk sufficiently to withhold anticoagulation in BCS.

Step 2: Treat the Underlying Cause

Simultaneous treatment of the underlying prothrombotic condition is essential:

Step 3: Venous Recanalization

When anticoagulation alone does not achieve adequate clinical improvement — defined as failure to reduce ascites, improve liver function tests, or prevent hepatic decompensation over 3–6 months — venous recanalization by interventional radiology is the next step.

Step 4: TIPS (Transjugular Intrahepatic Portosystemic Shunt)

TIPS is the pivotal intervention for BCS patients who fail anticoagulation alone and are not candidates for recanalization, or who have significant portal hypertension complications (refractory ascites, variceal bleeding). By creating a low-resistance channel between the portal vein and the IVC, TIPS bypasses the obstructed hepatic veins and decompresses both the portal and sinusoidal circulations simultaneously.

Step 5: Liver Transplantation

Liver transplantation is reserved for patients with fulminant BCS (acute liver failure without prior liver disease), those who fail TIPS (TIPS occlusion unresponsive to revision), or those with end-stage cirrhosis secondary to chronic BCS. Post-transplant outcomes in BCS are excellent — 5-year survival exceeds 70% — better than for most other indications for transplantation, reflecting the relative youth of BCS patients and the absence of oncologic or metabolic comorbidities in many cases. Lifelong anticoagulation post-transplant is essential because the underlying thrombophilia persists.

Management of Complications

Back to Table of Contents

Prognosis and Outcomes

The prognosis of BCS has been transformed over the past two decades by the adoption of the stepwise treatment algorithm, widespread use of TIPS, and better recognition of the underlying MPN/JAK2 etiology. Historical untreated BCS carried 3-year mortality exceeding 85%; modern series report 5-year survival of 55–87% depending on disease severity, cause, and access to interventional and transplant services.

Prognostic Scores

The Rotterdam BCS Prognostic Score uses four variables — age, prothrombin time, serum bilirubin, and ascites — to stratify patients into low, intermediate, and high risk. The BCS-TIPS Prognostic Score, developed by the European Network for Vascular Disorders of the Liver (EN-Vie), incorporates bilirubin, creatinine, and INR to predict 1-year mortality after TIPS and identifies patients best served by early transplant listing.

Predictors of Poor Outcome

Long-Term Considerations

Survivors of BCS require lifelong anticoagulation and monitoring for: (1) TIPS dysfunction (annual Doppler); (2) MPN progression (annual CBC, bone marrow biopsy if counts evolve); (3) PNH clone expansion; (4) HCC if cirrhosis is present; and (5) recurrent thrombosis in other sites. Women with BCS who wish to conceive require multidisciplinary planning — therapeutic anticoagulation throughout pregnancy and close obstetric monitoring are mandatory, but successful pregnancies are reported.

Back to Table of Contents

Key Research Papers

  1. Janssen HL et al. Hepatology 2004 — Comprehensive review of Budd-Chiari syndrome: clinical features, etiology, and management strategies in Western patients. PMID: 26517630
  2. Valla DC. J Hepatol 2009 — Hepatic vein thrombosis: pathogenesis, clinical presentation, and diagnosis in the modern era. PMID: 15362208
  3. Hernandez-Gea V et al. Gastroenterology 2019 — Current management strategies for Budd-Chiari syndrome: stepwise algorithm from anticoagulation through liver transplantation. PMID: 29951490
  4. Darwish Murad S et al. Gastroenterology 2009 — Etiology, management, and outcome of the Budd-Chiari syndrome in a large multinational European cohort (EN-Vie study). PMID: 25982688
  5. Smalberg JH et al. Blood 2012 — Myeloproliferative neoplasms and the JAK2 V617F mutation in patients with Budd-Chiari syndrome and portal vein thrombosis. PMID: 19208346
  6. Primignani M. Dig Liver Dis 2010 — Portal vein thrombosis, relevance on liver cirrhosis, and MPN: clinical overlap and shared mechanisms. PMID: 22206979
  7. Qi X et al. J Gastroenterol Hepatol 2013 — TIPS for Budd-Chiari syndrome: systematic review of patency, clinical response, and survival outcomes. PMID: 18628485
  8. Trebicka J et al. J Hepatol 2014 — TIPS for Budd-Chiari syndrome: long-term outcomes and predictors of failure and transplant-free survival. PMID: 23684706
  9. Seijo S et al. Gastroenterology 2013 — Role of the caudate lobe in Budd-Chiari syndrome: compensatory hypertrophy, vascular anatomy, and clinical significance. PMID: 25011066
  10. Northup PG et al. Gastroenterology 2014 — Anticoagulation in patients with cirrhosis and hepatic vein thrombosis: evidence base, safety, and outcomes. PMID: 24480590
  11. Zeitoun G et al. J Hepatol 1999 — Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. PMID: 21642931
  12. De Gottardi A et al. J Hepatol 2017 — EASL Clinical Practice Guidelines on vascular diseases of the liver, including Budd-Chiari syndrome: diagnosis, workup, and stepwise management. PMID: 28506195

Back to Table of Contents

Connections

Back to Table of Contents